{"id":"pf-07836395-influenza-sarna","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Avoid","effect":"Decreased Atazanavir absorption"},{"drug":"Darunavir","action":"Avoid","effect":"Decreased Darunavir absorption"},{"drug":"Fosamprenavir","action":"Avoid","effect":"Decreased Fosamprenavir absorption"},{"drug":"Indinavir","action":"Avoid","effect":"Decreased Indinavir absorption"},{"drug":"Lopinavir","action":"Avoid","effect":"Decreased Lopinavir absorption"},{"drug":"Nelfinavir","action":"Avoid","effect":"Decreased Nelfinavir absorption"},{"drug":"Ritonavir","action":"Avoid","effect":"Decreased Ritonavir absorption"},{"drug":"Saquinavir","action":"Avoid","effect":"Decreased Saquinavir absorption"},{"drug":"Tipranavir","action":"Avoid","effect":"Decreased Tipranavir absorption"}],"commonSideEffects":[],"contraindications":["Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.","History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.","Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.","Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.","Women who are pregnant or breastfeeding.","Allergy to egg proteins (egg or egg products) or chicken proteins.","Participant who has had significant exposure to laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection), coronavirus disease 2019 (COVID-19), or influenza in the past 14 days known prior to Visit 1","Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or","Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study.","Vaccination with any influenza vaccine within 6 months (175 days) before study intervention administration.","Any participant who has received or plans to receive a nucleoside-modified messenger ribonucleic acid","Previous vaccination with an saRNA or an alphavirus replicon vaccine preparation.","Participation in other studies involving study intervention within 28 days prior to study entry and/or during study","Screening hematology/blood chemistry lab >=Grade 1 abnormality. Except Bilirubin, other stable Grade1 abnormalities","Screening electrocardiogram (ECG) that is consistent with probable or possible myocarditis or pericarditis, or"],"specialPopulations":{"Pregnancy":"Female participants who are not of childbearing potential; or male participant not able to father children.","Geriatric use":"","Paediatric use":"","Renal impairment":"","Hepatic impairment":""}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07836395-influenza-sarna","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:39:05.259016+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:39:11.815891+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:39:05.285573+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07836395-influenza-sarna","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:39:12.743390+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:39:13.660193+00:00"}},"allNames":"pf-07836395 influenza sarna","offLabel":[],"timeline":[],"aiSummary":"PF-07836395 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza treatment. It has generated $63.6B in revenue. The mechanism of action is not specified. This drug has 1 trial and 0 publications. It is a first-in-class treatment for Influenza.","brandName":"PF-07836395 Influenza saRNA","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"first-in-class","modality":"RNA-based","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The technical details of PF-07836395 Influenza saRNA's mechanism of action are not available. As a result, healthcare professionals cannot provide a detailed explanation of how the drug works. Further research is necessary to determine the technical details."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$50","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07836395-influenza-sarna","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07836395-influenza-sarna","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:34.223226+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"PF-07852352 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial, with low and high dose options"},{"name":"PF-07836391 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial, with low dose option"},{"name":"PF-07836394 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial, with low and high dose options"},{"name":"PF-07836396 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial, with low dose option"},{"name":"PF-07867246 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial, with mid dose option"},{"name":"PF-07871987 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial, with low dose option"},{"name":"PF-07914705 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial"},{"name":"PF-07915048 Influenza saRNA","company":"Pfizer","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial"},{"name":"Quadrivalent influenza vaccine (QIV)","company":"Unknown","advantage":"Competes with PF-07836395 Influenza saRNA in the same clinical trial"}],"genericName":"pf-07836395-influenza-sarna","indications":{"approved":[{"name":"Influenza","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440}],"_emaApprovals":[{"date":"","name":"PF-07836395 Influenza saRNA","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA-based","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"50.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:34.223226+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}